Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Armandi

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Journal of Clinical Medicine|February 15, 2022
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Aurora Nicolosi, et al.
Current Oncology (Toronto, Ont.)|August 25, 2022
Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver DiseaseGian Paolo Caviglia, Aurora Nicolosi, Maria Lorena Abate, et al.
International Journal of Molecular Sciences|January 21, 2023
The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver DiseaseAngelo Armandi, Giorgia Colombo, Chiara Rosso, et al.
Minerva Gastroenterology|October 12, 2022
Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinomaAurora Nicolosi, Silvia Gaia, Alessandra Risso, et al.
Journal of Clinical Medicine|January 21, 2023
Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Ramy Younes, et al.
Journal of Clinical Medicine|March 19, 2020
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel DiseasesGian Paolo Caviglia, Chiara Rosso, Francesco Stalla, et al.
The American Journal of Gastroenterology|June 11, 2025
Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM CohortNuria Perez-Diaz-Del-Campo, Gabriele Castelnuovo, Arianna Ferro, et al.
Cancers|November 4, 2020
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral EtiologyGian Paolo Caviglia, Michela Ciruolo, Maria Lorena Abate, et al.
Journal of Personalized Medicine|June 27, 2024
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and ComprehensibilityNicola Pugliese, Davide Polverini, Rosa Lombardi, et al.
European Journal of Clinical Investigation|February 24, 2024
Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: A meta-analysisOvidio De Filippo, Gianluca Di Pietro, Marco Nebiolo, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Journal of Clinical Medicine|February 15, 2022
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Aurora Nicolosi, et al.
Current Oncology (Toronto, Ont.)|August 25, 2022
Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver DiseaseGian Paolo Caviglia, Aurora Nicolosi, Maria Lorena Abate, et al.
International Journal of Molecular Sciences|January 21, 2023
The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver DiseaseAngelo Armandi, Giorgia Colombo, Chiara Rosso, et al.
Minerva Gastroenterology|October 12, 2022
Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinomaAurora Nicolosi, Silvia Gaia, Alessandra Risso, et al.
Journal of Clinical Medicine|January 21, 2023
Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Ramy Younes, et al.
Journal of Clinical Medicine|March 19, 2020
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel DiseasesGian Paolo Caviglia, Chiara Rosso, Francesco Stalla, et al.
The American Journal of Gastroenterology|June 11, 2025
Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM CohortNuria Perez-Diaz-Del-Campo, Gabriele Castelnuovo, Arianna Ferro, et al.
Cancers|November 4, 2020
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral EtiologyGian Paolo Caviglia, Michela Ciruolo, Maria Lorena Abate, et al.
Journal of Personalized Medicine|June 27, 2024
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and ComprehensibilityNicola Pugliese, Davide Polverini, Rosa Lombardi, et al.
European Journal of Clinical Investigation|February 24, 2024
Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: A meta-analysisOvidio De Filippo, Gianluca Di Pietro, Marco Nebiolo, et al.
Pageof 13